pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 12·1 min read
save

Journalist reflects on challenges of reporting healthcare AI after fellowship

May 12, 2026·read at Endpoints ↗Neutral

The author participated in a journalism fellowship that focused on health technology reporting.

The experience underscored the importance of continuously examining the incentives that drive AI projects in medicine.

It points out that financial and commercial motives can shape how AI tools are described, so reporters need to stay vigilant.

The writer urges readers and fellow journalists to keep these considerations in mind when covering health AI stories.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “What I learned at a journalism fellowship about covering healthcare AI”

read at Endpoints ↗
81 words · retrieved May 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 4h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 6h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints
  • 8h agoGilead’s pill posts stronger colitis remission rates than EntyvioEndpoints
  • 8h agoEyePoint's Phase 3 failure; Lilly's China drug delivery dealEndpoints